In this study, researchers investigated the genetic inhibition of ATP citrate lyase, a relatevely new type of LDL lowering drug with poorly understood molecular mechanism.
The objective of this study was to provide a biologic context for interpreting the results of the completed trials of ATP citrate lyase inhibitors and how the effect of this inhibitor correlates with HMGCR inhibitor. The results confirmed the mechanism by which ATP citrate lyase inhibition lowers plasma LDL cholesterol levels, that is, by reducing the concentration of LDL particles through up-regulation of the LDL receptor. This study provides validation for ATP citrate lyase inhibition as a new genetic target in drug development.
Latest news about Nightingale